oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The presence of PD-L1 in men with localized prostate cancer
Örebro universitet, Institutionen för medicinska vetenskaper. Department of Urology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden.
Molecular Pathology Laboratory, Addarii Institute of Oncology, Department of Hematology-Oncology, University of University of Bologna, Bologna, Italy.
Molecular Pathology Laboratory, Addarii Institute of Oncology, Department of Hematology-Oncology, University of Bologna, Bologna, Italy .
Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Urology, Örebro University Hospital, Örebro, Sweden.ORCID-id: 0000-0001-5533-7899
2017 (engelsk)Inngår i: Medical research archives, ISSN 2375-1916, Vol. 4, nr 8Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Recent therapeutic strategies for different cancer types have focused on targeting immune check-points, such as programmed death-1 (PD-1) and its ligand PD-L1. However, it was recently reported that men with castration-resistant prostate cancer did not respond to PD-1 blockade as monotherapy. The unresponsiveness could potentially be explained by low expression of PD-L1 on prostate tumor cells. This study investigated the expression of PD-L1 on tumor cells and tumor infiltrating lymphocytes (TILs) in men with primary prostate cancer.

Material and Methods: Immunohistochemical analysis of PD-L1 expression was performed in a cohort of men undergoing transurethral resection of the prostate and diagnosed with prostate cancer. The expression was evaluated in tissue microarrays from 522 patients with at least 25 years of follow-up.

Results: Only four of the 522 evaluated cases were positive for PD-L1, positivity on tumor cells were found in three of the cases, of which one case also had positivity on TILs, while a fourth case only had positivity on TILs.

Conclusion: Our data suggest that treatments targeting the PD-1/PD-L1 interaction may not be successful as monotherapy in patients diagnosed with localized prostate cancer due to low expression of PD-L1.

sted, utgiver, år, opplag, sider
Walnut CA, USA: KEI Journals , 2017. Vol. 4, nr 8
Emneord [en]
Prostate cancer, PD-1, PD-L1
HSV kategori
Forskningsprogram
Onkologi
Identifikatorer
URN: urn:nbn:se:oru:diva-57849DOI: 10.18103/mra.v4i8.742OAI: oai:DiVA.org:oru-57849DiVA, id: diva2:1099111
Tilgjengelig fra: 2017-05-29 Laget: 2017-05-29 Sist oppdatert: 2018-09-12bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Davidsson, SabinaCarlsson, Jessica

Søk i DiVA

Av forfatter/redaktør
Davidsson, SabinaCarlsson, Jessica
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 263 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf